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phenotype,  with  elevated  L‐lactate  production.    We  show  that  this  metabolic  inflexibility  could  be  rapidly‐
induced,  after  only  1  hour  of  DPI  treatment.  Remarkably,  the  mitochondrial  inhibitory  effects  of  DPI  were
reversible,  and DPI  did  not  induce  ROS  production.  Cells maintained  in DPI  for  1 month  showed  little  or  no
mitochondrial activity, but  remained viable. Thus,  it appears  that DPI behaves as a new  type of mitochondrial
inhibitor, which maintains cells in a state of metabolic‐quiescence or “suspended animation”.  In conclusion, DPI
treatment  can  be  used  to  acutely  confer  a  mitochondrial‐deficient  phenotype,  which  we  show  effectively
depletes  CSCs  from  the  heterogeneous  cancer  cell  population.  These  findings  have  significant  therapeutic
implications  for  potently  targeting  CSCs,  while  minimizing  toxic  side  effects.    We  also  discuss  the  possible
implications  of DPI  for  the  aging  process.  Interestingly,  previous  studies  in  C.  elegans  have  shown  that DPI
prevents the accumulation of lipofuscin (an aging‐associated hallmark), during the response to oxidative stress.
Our  current  results  are  consistent  with  data  showing  that  flavins  (FAD,  FMN  and/or  Riboflavin)  are  auto‐
fluorescent markers of i) increased mitochondrial “power” (OXPHOS) and ii)  elevated  CSC  activity.  Finally,  we 











Cancer stem-like cells (CSCs) are thought to be one of 
the main drivers of poor clinical outcome, in a wide 
variety of tumor types and especially in advanced 
disease states. This is because CSCs are responsible for 
initiating the process of treatment failure, ultimately 
resulting in tumor recurrence and distant metastasis [1-
4].  Unfortunately, current conventional therapies were 
not designed to target CSCs; so, new drug development 
in this clinical area is warranted and is a high trans-
lational priority [5]. 
 
Recently, we proposed that CSCs have an increased 
mitochondrial mass and are functionally dependent on 
mitochondrial biogenesis and OXPHOS for their 
successful propagation, in an anchorage-independent 
fashion [6-8]. In support of this mechanistic hypothesis, 
we showed that FDA-approved antibiotics that behave 
as inhibitors of mitochondrial biogenesis (Azithro-
mycin, Doxycycline and Tigecycline) or OXPHOS 
(Pyrvinium pamoate, Atovaquone and Bedaquiline), all 
effectively restrict the propagation of CSCs [9-13]. 
Other FDA-approved drugs (or dietary supplements) 
with anti-OXPHOS activity, also targeted CSCs 
(Berberine, Irinotecan, Sorafenib and Niclosamide) 
[14]. Similarly, the warfarin-like drug Dicoumarol, was 
sufficient to overcome tamoxifen-resistance in ER(+) 
cancer cells, by targeting the protective effects of 
NQO1 on cancer cell mitochondria [15].  
 
Because of these promising findings, here we decided to 
intensify our search for new metabolic inhibitors, by 
screening a library of FDA-approved drugs and other 
related test compounds, with known targets and 
established mechanisms of action. More specifically, we 
restricted our search to compounds that significantly 
reduced ATP production, but did not induce cell death, 
to avoid drugs with acute toxic side-effects.  
 
This focused approach allowed us to identify DPI as a 
fast-acting, reversible and “non-toxic” mitochondrial 
inhibitor, which preferentially targets the propagation of 
CSCs. Remarkably, DPI induces a “chemo-quiescence” 
phenotype, but without resulting in massive cell death. 
DPI prevented the propagation of CSCs, with  an  IC-50  










“bulk” cancer cell population or normal fibroblasts.  
 
Furthermore, DPI selectively reduced the CD44+/CD24- 




Screening for novel “non-toxic” mitochondrial 
inhibitors: identification of DPI as a top hit 
compound 
 
Recently, we developed a new approach for the 
therapeutic targeting of CSCs, focused specifically on 
mitochondrial metabolism. A schematic diagram 
summarizing this metabolic approach to drug discovery 
and functional validation is illustrated in Figure 1.  
 
Briefly, the screening assay was designed to identify 
compounds, which can functionally induce ATP-
depletion, but without inducing cell death, to avoid 
toxic side-effects. Initially, a sub-set of the Tocriscreen 
Compound library (>500 chemical entities) was 
subjected to phenotypic drug screening, at a 
concentration of 20 µM. Subsequently, positive hits 
were re-screened at a lower concentration (10 µM).  
  
As DPI (Diphenyleneiodonium chloride) was identified 
as our top hit compound, we subjected it to further 
functional validation, including: i) mammosphere 
assays (for assessing potential anti-cancer stem cell 
activity); ii) metabolic flux analysis (to determine 
specific effects on oxygen consumption), as well as iii) 
flow cytometry (to monitor the expression of well-
established CSC markers).  
 
Figure 2 demonstrates that DPI selectively depletes 
ATP levels, without inducing massive cell death. 
Briefly, human breast cancer cells (MCF7) were treated 
with DPI for 72 hours. Then, they were subjected to 
fluorescent Hoechst DNA-staining (to normalize for cell 
number); by employing CellTiter-Glo as a probe, we 
were able to use luminescence to measure ATP content 
in the same wells. Importantly, at 72 hours of treatment, 
500 nM DPI dramatically reduced ATP levels, but did 
not significantly induce any cell death, as the number of 
cells attached to the plate remained unchanged (as 





times more potent than Palbociclib  (IC‐50 = 100 nM), which  is an FDA‐approved CDK4/6  inhibitor, that broadly
targets proliferation in any cell type, including CSCs.  










































































In parallel, cell viability assays were carried out to 
evaluate its potentially toxicity. Figure 3 shows that DPI 
does not significantly affect cell viability, even after 5 
days of treatment. Cell viability was assessed by employ-
ing the SRB-assay, which measures protein content.  
After 5 days of treatment, DPI showed little or no toxicity 
in MCF7 cells, at a concentration as high as 33 nM. 
Virtually identical results were also obtained with normal 
fibroblasts (hTERT-BJ1), which showed little or no toxic 































Figure 1. Diagram  illustrating  the main  steps of our drug
discovery work‐flow.  (i) Phenotypic drug  screening. A  sub‐set
of the Tocriscreen compound library was subjected to phenotypic
drug screening, at a concentration of 20 µM. The screen was set
up  to  specifically  identify  compounds  which  can  functionally
induce ATP‐depletion, without inducing cell death.  Subsequently,
positive hits were  re‐screened at a  lower concentration  (10 µM).
(ii)  Functional  validation.  Hit  compounds  were  then  further
validated using mammosphere assays (for assessing potential anti‐
cancer  stem  cell  activity). Metabolic  flux  analysis  (to  determine
specific  effects  on  oxygen  consumption),  flow  cytometry  and
viability assays were also carried out.    (iii) Top hit compound. The
structure  of  DPI  (Diphenyleneiodonium  chloride),  the  top  hit
compound,  is  shown.  Importantly,  DPI  is  known  to  functionally


















































Validation of DPI as a potent mitochondrial inhibitor 
 
To functionally validate that DPI behaves as a strong 
mitochondrial inhibitor, we subjected DPI-treated breast 
cancer cells to a “mitochondrial stress test”. Figure 4 
illustrates that DPI potently inhibited mitochondrial 
respiration. First, MCF7 cells were exposed to 24 hours 
of treatment with DPI, at a concentration of 2.5 to 50 
nM. Then, the treated cells were analyzed with the 
Seahorse XFe96, which measures the OCR (the oxygen 
consumption rate). Importantly, at a concentration of 
2.5 nM, DPI had little or no effect. However, at 5 nM, 
basal respiration was reduced by ~ 50%.  Finally, at 10 
nM, the basal respiration rate was decreased by ~85%, 










































Induction of glycolysis and L-lactate production by 
DPI 
 
To determine if the anti-mitochondrial effects of DPI 
induce a reactive glycolytic response, we next subjected 
DPI-treated breast cancer cells to a “glycolytic stress 
test”. Figure 5 highlights that DPI potently induced a 
glycolytic phenotype. MCF7 cells were subjected to 
metabolic flux analysis with the Seahorse XFe96, which 
also measures ECAR (the extracellular acidification 
rate), as a surrogate marker for L-lactate production. 
After 24 hours of treatment with DPI (2.5 nM), little or 
no effect was observed.  However, at 10 nM DPI, 




content.  Note  that  after  5  days  of  incubation,  DPI  shows  little  or  no  toxicity  in MCF7  cells,  at  a
concentration as high as 33 nM. However, some toxicity was observed at 100 nM. Similarly, normal
fibroblasts (hTERT‐BJ1) showed little or no toxic effects at up to 100 nM, after 5 days of incubation.  













































To confirm that the increased ECAR we observed 
corresponded to L-lactate production, L-lactate levels 
were measured directly using the ISCUS-flex 
microdialysis analyser.  After treatment with DPI (5 or 
50 nM) for 1, 3 or 5 days, the cell culture media from 
MCF7 cells was used to measure L-lactate content.  
 
Figure 6 shows that DPI induced significant L-lactate 
production, nearly doubling the amount of lactate 















































DPI treatment effectively inhibits the propagation of 
CSCs, without increasing ROS production  
 
Figure 7 highlights that DPI dose-dependently inhibited 
CSC propagation, as assessed using the mammosphere 
(3D tumor sphere) assay.  To determine the potential 
anti-CSC activity of DPI, MCF7 cells were first seeded 
into low-attachment plates and allowed to form mam-
mospheres over a period of 5 days. The mammosphere 
assay was performed over the range of 0.2 nM to 10 µM 
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CSC propagation, in a concentration-dependent manner, 
with an IC-50 of 3.23 nM.  
 
To further validate our findings, we used a second 
independent approach to quantitate “stemness” in 
cancer cells, by employing specific cell surface markers, 
namely fluorescent antibody probes directed against 
CD44 and CD24. In this context, the CD44+/CD24- cell 
population represnts the CSC-enriched fraction.  
 
Figure 8 shows that DPI selectively eliminates these 
CSCs from the total cell population. Briefly, MCF7 












































presence of DPI (5, 10 and 50 nM). Then, the cells were  
were harvested and subjected to FACS analysis to 
determine the levels of CSC markers. Interestingly, the 
CD44+/CD24- cell population was dose-dependently 
reduced by DPI treatment, with an IC-50 of 10 nM.   
 
One possible mechanism by which DPI inhibits CSC 
propagation is by simply inducing mitochondrial ROS 
production. To address this issue, we directly determined 
the effects of DPI, after 24 hours of treatment, on mito-
chondrial ROS production, over the range of 5 to 50 nM. 
Mitochondrial ROS production was monitored by FACS 






































































































Figure 9 illustrates that at a concentration of 5 nM, 
DPI failed to induce any detectable mitochondrial 






















































vehicle alone. In contrast, 50 nM DPI induced the 
same amount mitochondrial ROS as 500 nM 
Rotenone, which served as a positive control.  
Figure 6. DPI drives the production of L‐lactate.  After treatment with DPI (5 or 50 nM) for 1, 3 or 5
days, the cell culture media from MCF7 cells was subjected to analysis using the ISCUS‐flex microdialysis






Note  that  DPI  markedly  reduced  CSC  propagation,  with  an  IC‐50  of  3.23  nM.  The
mammosphere assay was performed over the range of 0.2 nM to 10 µM.  
 
















































































































Figure 8. DPI  selectively eliminates CSCs  from  the  total
cell  population.  MCF7  cells  were  cultured  for  5  days  as
monolayers, in the presence of DPI (5, 10 and 50 nM). Then, the
cells  were  harvested  and  subjected  to  FACS  analysis  to
determine the  levels of CSC markers.   Panel  (A) shows that the
CD44+/CD24‐  cell  population  (which  serves  as  a  marker  for
breast  CSCs)  is  dose‐dependently  reduced  by  DPI  treatment,
with an IC‐50 of 10 nM.  Panel (B) contains dot plots showing the
double  fluorescent  CD44+/CD24‐  FACS  assay.  Note  that  the
signal  has  significantly  decreased  in  the  lower  right  quadrant
(Q1), after DPI treatment.  * p<0.05, ** p<0.01. 
Figure 9. Effect of DPI  treatment on mitochondrial ROS
production.  The  effects  of  DPI  on  mitochondrial  ROS
production were determined over the range of 5 to 50 nM. Note
that  at  a  concentration  of  5  nM,  DPI  failed  to  induce
mitochondrial ROS production.  In  contrast, 50 nM DPI  induced
the  same  amount  of mitochondrial ROS  as  500  nM Rotenone,
which  was  used  as  a  positive  control.  Mitochondrial  ROS
production was monitored by FACS analysis, using MitoSOX as a
fluorescent indicator.  * p<0.05. 
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Therefore, the same concentration of DPI (5 nM) that 
inhibited mammosphere formation by >50% failed to 
increase mitochondrial ROS production. As such, the 
effects of low-dose DPI on “stemness” in cancer cells 




















































In direct support of DPI’s high selectivity in the targeting 
the CSC population, DPI had no effect on programmed 
cell death (apoptotic rate) in MCF7 cell monolayers, as 
measured quantitatively by FACS analysis, using a 





















































































































DPI is a fast-acting, reversible, “non-toxic” 
mitochondrial inhibitor 
 
Given DPI’s high potency, we next assessed its ability 
to rapidly affect cell metabolism. Figure 11 demons-
trates the remarkably fast-action of DPI on mito-
chondrial respiration. After as little as 1 hour of DPI 
treatment, the mitochondrial oxygen consumption rate 
(OCR) was progressively reduced, over a concentration 
range of 10 to 100 nM.  Basal respiration was inhibited 
with an IC-50 of 50 nM.  
 
Similarly, DPI rapidly induced a reactive glycolytic 
phenotype. Glycolysis progressively increased, over a 
concentration range of 5 to 100 nM. Figure 12 shows 
that glycolysis effectively doubled.  
 
The effects of DPI also appeared to be highly reversible. 
To assess the reversibility of DPI’s effects, MCF7 cells 
were first subjected to DPI treatment for 24 hours 
(Figures 13 and 14). Then, DPI was removed and the 
cells were cultured for an additional 24 hours, to allow 
recovery. DPI-treatment, “wash-out” and recovery was 
performed over a concentration range of 10 to 50 nM 
DPI. At 10 nM DPI, there was a near complete recovery 
of basal respiration, approaching 100%, after only 24 
hours. Higher concentrations showed significant 





























Figure  11.  DPI  rapidly  induces  the  inhibition  of
mitochondrial respiration.  Even with as little as 1 hour of DPI
treatment, the mitochondrial oxygen consumption rate (OCR) was
progressively  reduced,  over  a  concentration  range  of  10  to  100
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Surprisingly, long-term treatment with DPI was also 
relatively “non-toxic”.  To determine the long-term 
effects of DPI (10, 25 and 50 nM), MCF7 cells were 
cultured for 1 month, in the presence of the drug. Then, 
mitochondrial respiration was assessed. Figure 15A 
illustrates that these concentrations all show near 
complete inhibition of respiration. Importantly, at a DPI 
concentration of 10 nM, the morphology and density of 




DPI targets mitochondrial metabolism and 
eliminates CSCs 
 
In this report, we conducted a high-throughput drug 
screen to discover novel mitochondrial inhibitors. More 
specifically, this screening assay was engineered to 
select chemical entities that potently reduce ATP levels, 
but do not induce cell death. With this strategy, DPI was 
identified a top hit compound.  More specifically, DPI 
induced a state of metabolic-quiescence, which potently 
prevented CSC propagation (IC-50 = 3.2 nM). 
Complementary findings were also provided using well-
established CSC markers (CD44 and CD24). 
Surprisingly, DPI treatment selectively depleted the 
CSC sub-population (CD44+/CD24-) from the total 
cancer cell population. We also quantitatively evaluated 




























using the Seahorse XFe96 metabolic flux analyzer. For 
example, DPI, at a concentration of only 10 nM, 
effectively inhibited OXPHOS and ultimately ATP 
production, by more than 90% overall. As a 
consequence, DPI treatment induced a reactive 
glycolytic phenotype, resulting in the production of high 
levels of L-lactate. The metabolic effects of DPI had a 
rapid onset and could be detected even after only 1 
hour. In addition, the effects of DPI appeared to be 
largely reversible, probably because low-dose DPI 
failed to induce mitochondrial ROS production. Basal 
respiration was restored to nearly 100% after 24 hours 
of treatment, followed by 24 hours of recovery, at a 
concentration of 10 nM. To assess the potential long-
term effects of DPI, cells were cultured for up to 1 
month with DPI treatment. During long-tern culture, 
little or no mitochondrial activity was observed; 
however, the cells remained viable.  
  
In summary, DPI represents a new class of 
mitochondrial inhibitors that induced a metabolically 
quiescent state, which progressively depleted both i) 
ATP levels and ii) the CSC sub-population. As a result, 
our current findings have important therapeutic 
implications, for targeting CSCs, while reducing 
potentially toxic complications. Our findings provide 
further evidence that it is possible to identify potent 
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What are the precise mechanism(s) by which DPI 
targets CSCs? 
 
The exact mechanism(s) by which DPI targets CSCs 
remains largely unknown and will require further 
experimental investigations.   
 
However, DPI is thought to act by binding to and 
targeting flavin-containing oxidase enzymes, many of 
which reside within mitochondria [16-18]. There are 90 
flavo-proteins that are encoded within the human 
genome [17,18]. It has been proposed that DPI can 
chemically react with FMN (flavin mononucleotide), 










































A comparison of the structures of DPI and FMN is 
shown in Figure 16. 
 
Importantly, flavin-containing enzymes include three 
protein components of mitochondrial Complex I, which 
are NDUFV1 (51 kD), NDUFV2 (24 kD) and NDUFV3 
(10 kD) [16,17]. However, SDHA is also a flavo-
protein that is part of both mitochondrial Complex II 
and the Krebs cycle. As such, DPI has been proposed to 
act by inhibiting the mitochondria, mainly at the levels 
of Complex I and II [18].  
 
Using GeneCards as a bioinformatic reference tool, we 
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ducts are localized to mitochondria. This may explain 
the exceptional potency of DPI, in targeting 
mitochondrial function in the low nano-molar range 








































Therefore, we speculate that the actions of DPI may be 
via the induction of a mitochondrial deficiency in FMN 
or FAD or by inactivating flavin-containing enzymes in 
CSCs (Figure 17).  In this context, it is interesting to 
note that Riboflavin (Vitamin B2) is the biochemical 
precursor of FAD and FMN. Moreover, Riboflavin is 
auto-fluorescent and has been shown to correlate with 
both i) high mitochondrial OXPHOS capacity [19] and 
ii) increased CSC activity [20].  This property should 
also allow us to monitor the response to DPI therapy, by 
using the auto-fluorescent (AF) imaging of Flavins 
(Riboflavin, FMN and/or FAD), to visualize CSCs and 
cellular heterogeneity within the tumor tissue [21].  
An additional mechanism for DPI’s effects on 
mitochondria has also been proposed. In this scenario, 
DPI inhibits ROS production (i.e., superoxide anion), 
by preventing reverse electron transport from succinate 
at mitochondrial Complex I [22], without affecting 
forward electron transport. This essentially means that 
DPI is preventing the production on an unwanted side 
reaction, which contributes to unnecessary ROS pro-
































A Riboflavin-deficiency targets mitochondrial 
complexes I & II, inhibiting OXPHOS 
 
Since DPI targets flavin-containing enzymes, its effects 
on mitochondrial function may be explained by the 
pharmacological induction of an acute Riboflavin 
(Vitamin B2) deficiency. Consistent with this hypothe-
sis, when mammalian HepG2 cells were cultured in 
Riboflavin-free media, proteomics analysis revealed 
that key components of mitochondrial complex I 
(NDUFS1; NDUFV2) and complex II (SDHA) were 
significantly reduced (by up to 5-fold), as were many 
other mitochondrial-related proteins, such as AIFM1, 
DLD, MCAD and NQO1 [23]. Thus, a Riboflavin-
deficiency directly targets the steady-state expression 
levels of OXPHOS-related proteins of mitochondrial 
Figure 16. The chemical structures of (A) DPI and (B) FMN
are compared. It has been proposed that the effects of DPI are
mediated  through  the general  inhibition of  flavo‐enzymes,  such
as  mitochondrial  Complex  I  (NADH  dehydro‐genase),  via  the
targeting  of  FMN.  The  three  known  flavin‐containing  protein
components of Complex I are: NDUFV1 (51 kD), NDUFV2 (24 kD)
and NDUFV3  (10 kD).  It has been suggested  that DPI chemically
reacts with FMN, interrupting its function and impairing electron
transport.  In  the  human  genome,  there  are  ~90  flavo‐proteins;
more than two‐thirds require FAD, while only ~15% require FMN.





CSCs.    Flavins  (FMN,  FAD  and  Riboflavin)  have  been  indepen‐
dently  used  as  markers  for  high  mitochondrial  OXPHOS  or 
increased CSC activity.   However,  it remained unknown whether 
flavins were  selectively  required  for CSC propagation. Here, we 
showed  that  DPI,  which  is  known  to  specifically  target  flavin‐
containing  enzymes,  behaves  as  a  powerful  mitochondrial 
OXPHOS  inhibitor  and  successfully  eradicates  CSCs  with  high 
potency,  in  the  low nano‐molar range. Therefore,  these  findings 
provide the first proof‐of‐concept that inhibiting flavin‐containing 
enzymes is a new viable strategy for effectively targeting CSCs.  
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complex I and II, as predicted. However, it should be 
noted that Riboflavin also plays a wider role in 
mitochondrial metabolism, by promoting fatty acid 
oxidation (FAO), as well as functionally stimulating 
mitochondrial biogenesis and driving the proper folding 
of complex IV [24-29].  
 
Furthermore, dietary restriction of Riboflavin 
significantly reduced tumor burden (both lesion number 
and size), in a spontaneous model of murine mammary 
tumorigenesis (C3H-mice) [30,31]. Similarly, DPI 
treatment significantly reduced tumor growth in mice 
xenografted with colon cancer cell lines [32]. However, 
these investigators did not evaluate the effects of 
Riboflavin or DPI, on the status of the CSC population.  
 
Possible implications for aging 
 
Mitochondria have been directly implicated in the 
process of aging. However, their exact role remains a 
hotly-debated topic. Nevertheless, it is interesting to 
speculate that DPI could be used to keep normal cells in 
a state of metabolic-quiescence or “suspended anima-
tion”, akin to hibernation, which might be extremely 
useful in slowing or reversing the aging process.  
 
In support of this assertion, previous studies in C. 
elegans have shown that DPI prevents the accumulation 
of lipofuscin (an aging-associated by-product or 
marker), during the response to oxidative stress [33]. 
This intriguing possible use for DPI should be explored 
further.  
 
Targeting other vitamins for anti-cancer therapy: 
Anti-folates are a successful therapeutic strategy for 
targeting rapidly-dividing cells and infectious 
parasites 
 
Is there any evidence that targeting the metabolism of 
other vitamins can be used as a successful anti-cancer 
strategy?  The best example is Vitamin B9, also known 
folic acid or folate.   
 
Anti-folates are anti-metabolites that block or disrupt 
the actions of folate.  Most anti-folate drugs exert their 
effects by targeting dihydrofolate reductase (DHFR).  
Folate serves as a co-factor for many biosynthetic 
enzymes (i.e., methyltransferases) that drive methio-
nine, serine, purine and thymidine biosynthesis.  
Examples of anti-folate drugs that are FDA-approved 
include: Methotrexate; Pemetrexed; Proguanil; 
Pyrimethamine; and Trimethoprim.   
 
The actions of anti-folates preferentially target rapidly 
dividing cells, especially during DNA-synthesis (the S-
phase of the cell cycle). Currently, both Methotrexate 
and Pemetrexed are routinely used for the treatment of 
various cancer types, such as osteosarcoma, non-small 
cell lung carcinoma, mesothelioma and hematologic 
malignancies.  Therefore, anti-folate therapy is consi-
dered as a successful strategy for treating cancer and 
various infectious parasitic diseases, such as malaria, 
toxoplasmosis and pneumocystis pneumonia.  
 
However, anti-folates also have significant side effects, 
because they also affect the proliferation of normal 
cells, leading to nausea, vomiting, abdominal pain, 





In summary, we have identified DPI as a mitochondrial 
inhibitor for the specific targeting of CSCs, in a 
heterogeneous population of cells.  
 
DPI is one of the most potent and highly-selective CSC 
inhibitors discovered to date. For example, DPI is ~30 
times more potent than Palbociclib (IC-50 ~ 100 nM), 





























This provides a new impetus to create novel analogues 
of i) DPI (Diphenyleneiodonium chloride) and ii) DPI-
related compounds (Diphenyliodonium chloride) 
(Figure 18), using medicinal chemistry, to optimize this 
Figure  18.  Comparison  of  the  structures  of  (A)
Diphenyleneiodonium (DPI), with the related compound
(B)  Diphenyliodonium  chloride.  Note  the  key  similarities
between these two chemical structures. Both of these classes of
molecules target flavin‐containing proteins.  
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very promising and potent anti-CSC activity. We 
propose to call these new molecules “Mitoflavoscins”.   
In the broadest sense, “Mitoflavoscins” would be 
considered as any small molecule(s) or peptide(s) that 
bind to flavin-containing enzymes [or actively depletes 
FMN, FAD or Riboflavin from cells] and, as a 
consequence, inhibits mitochondrial function.  
 




MCF7 cells were purchased from ATCC (American 
Type Culture Collection). Gibco-brand cell culture 
media (DMEM) was purchased from Life Technologies.  
 
Phenotypic drug screening, with a metabolic ATP-
depletion assay 
 
MCF7 cells (6,000 cells/well) were plated into black 
clear-bottom 96-well plates and incubated overnight 
before treatment. Then, a sub-set of the Tocriscreen 
compound library (560 compounds) were subjected to 
phenotypic drug screening at a concentration of 20 μM, 
to identify which compounds functionally induce ATP-
depletion, before inducing cell death.  Subsequently, 
positive hits were re-screened at 10 μM, to identify the 
top 11 compounds that most potently induced ATP-
depletion. Compounds were tested after 72 hours of 
incubation and experiments were performed in 
triplicate. After treatment, media was aspirated from the 
wells and plates were washed with warm PBS 
(supplemented w/ Ca2+ and Mg2+). Then, cells were 
incubated with a Hoechst 33342 (Sigma) staining 
solution (10 µg/ml) for 30 min and washed with PBS. 
Fluorescence was read with a plate reader using 
excitation/emission wavelengths at 355/460-nm. Then, 
the CellTiter-Glo luminescent assay (Promega) was 
performed to measure metabolic activity (ATP content) 
in the very same wells that were treated with a given 
compound. Assays were performed according to the 
manufacturer’s protocol. Fluorescence (Hoechst 
staining) and luminescence intensities (ATP content) 
were normalized to vehicle-alone treated controls and 
were displayed as percentages.  
 
Cell viability assay 
 
The Sulphorhodamine (SRB) assay is based on the 
measurement of cellular protein content. After treatment 
for 72 hours with DPI in 96-well plates, the cells were 
fixed with 10% trichloroacetic acid (TCA) for 1 hour in 
the cold room, and were dried overnight at room 
temperature. Then, cells were incubated with SRB for 
15 min, washed twice with 1% acetic acid, and air dried 
for at least 1 hour. Finally, the protein-bound dye was 
dissolved in a 10 mM Tris, pH 8.8, solution and 
analyzed using a plate reader at 540-nm. 
 
Metabolic flux analysis using the seahorse XFe96 
 
Extracellular acidification rates (ECAR) and real-time 
oxygen consumption rates (OCR) for MCF7 cells were 
determined using the Seahorse Extracellular Flux 
(XF96) analyzer (Seahorse Bioscience, MA, USA). 
MCF7 cells were maintained in DMEM supplemented 
with 10% FBS (fetal bovine serum), 2 mM GlutaMAX, 
and 1% Pen- Strep. 8,000 cells per well were seeded 
into XF96-well cell culture plates, and incubated 
overnight at 37°C in a 5% CO2 humidified atmosphere. 
Next day, cells were washed in pre-warmed XF assay 
media (for OCR measurement, XF assay media was 
supplemented with 10mM glucose, 1mM Pyruvate and 
adjusted at pH 7.4). Cells were then maintained in 175 
μL/well of XF assay media at 37°C, in a non-CO2 
incubator for 1 hour. During incubation, 25 μL of of 
80mM glucose, 9μM oligomycin, 1M 2-deoxyglucose 
(for ECAR measurement) and 25 μL of 10μM 
oligomycin, 9μM FCCP, 10μM rotenone, 10μM anti-
mycin A (for OCR measurement) in XF assay media 
was loaded into the injection ports of the XFe-96 sensor 
cartridge. During the experiment, the instrument 
injected these inhibitors into the wells at a given time 
point, while ECAR/OCR was measured continuously. 
ECAR and OCR measurements were normalized by 
protein content (Sulphorhodamine B assay). Data sets 
were analyzed by XFe-96 software, using one-way 
ANOVA and Student’s t-test calculations. All expe-
riments were performed in triplicate. 
 
Measurement of L-lactate levels in cell culture media 
 
Culture media were collected, centrifuged and analyzed 
with ISCUS-flex Microdialysis Analyzer after treatment 
of MCF7 cells with various concentrations of DPI for 1, 
3 or 5 days. First, calibration of the instrument was 
performed by samples provided by the manufacturer. 
Then L-lactate levels were measured and normalized to 
samples taken from MCF7 cells treated with vehicle 
only.   
 
Mammosphere formation assays 
 
A single cell suspension of MCF7 cells was prepared 
using enzymatic (1x Trypsin-EDTA, Sigma Aldrich) 
and manual disaggregation (25 gauge needle. Cells were 
then plated at a density of 500 cells/cm2 in mammo-
sphere medium (DMEM-F12/ B27 / 20-ng/ml EGF/Pen- 
Strep) in non-adherent conditions, in culture dishes 
coated with (2-hydroxyethylmethacrylate) (poly-
HEMA, Sigma). Cells were grown for 5 days and 
maintained in a humidified incubator at 37°C at an 
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atmospheric pressure in 5% (v/v) carbon dioxide/air. 
After 5 days in culture, spheres >50 μm were counted 
using an eye-piece graticule, and the percentage of cells 
plated which formed spheres was calculated and is 
referred to as percent mammosphere formation, 
normalized to vehicle-alone treated controls. Mammo-
sphere assays were performed in triplicate and repeated 
three times independently. 
 
Mitochondrial ROS measurement 
 
Production of superoxide by mitochondria was 
measured by the MitoSOX Red mitochondrial super-
oxide indicator (ThermoFisher Sci., M36008). 3 x105 
MCF7 cells/well were plated in 6-well plates in 
complete media supplemented with 10% heat-
inactivated FBS. The next day, cells were treated with 
DPI (5, 50 nM) or Rotenone (0.5 µM) for 24 hours. 
Vehicle alone (DMSO) for control cells were processed 
in parallel. At least 30,000 events were recorded by 
FACS using Fortessa (BD Bioscience). Importantly, 
three biological replicates (repeats) were analyzed in 
independent experiments. Results are the average of the 
mean of each experiment and are expressed as 
percentages of mean fluorescence intensity normalized 
to control. `Comp` in the title of X-axis means data 
were normalized with autocalculated compensation.  * 
p<0.05, ** p<0.01, ns not significant. One-way 
ANOVA was used with Dunnett’s multiple comparisons 
test. A Brown-Forsythe test was used to test the equality 




1 x 105 MCF7 cells were plated in 6-well plates in 
complete media supplemented with 10% heat-
inactivated FBS. Next day, cells were treated with DPI 
(5, 10, 50 nM) for 5 days. Vehicle alone (DMSO) 
control cells were processed in parallel. Briefly, 30,000-
50,000 live cells, as identified by 7-AAD dye staining, 
were analyzed for CD24/CD44 expression. We 
employed CD24 (IOTest CD24-PE, Beckman Coulter) 
and CD44 (APC mouse Anti-Human CD44, BD 
Pharmingen) antibodies for FACS-analysis, using the 
BD LSR Fortessa (BD Bioscience). Results are the 
average of three biological replicates (repeats) and are 
expressed as percentages of mean fluorescence 
intensity, normalized to the control. * p<0.05, ** 
p<0.01, *** p<0.001. One-way ANOVA was used with 




Cell death was quantified by flow cytometry using 
propidium iodide (PI) and Annexin V-FITC, essentially 
as previously described [35].  Briefly, 300,000 MCF7 
cells were plated in 6 multiwell plate in complete media 
supplemented with 10% HiFBS. Next day, cells were 
treated with DPI (5, 10, 50 nM). Vehicle alone (DMSO) 
for control cells were processed in parallel. After 24 
hours, cells were harvested and washed in cold 
phosphate-buffered saline (PBS). Cells were recentri-
fuged and supernatants were discarded. Then, cells were 
re-suspended in 100 µl of annexin-binding buffer. Then, 
the annexin–FITC conjugate (5 μl) and PI (1 μL) were 
added and incubated in the dark at room temperature for 
15 min. After the incubation period, reaction was stopped 
by adding 400 μL of annexin-binding buffer. Cells were 
then analyzed by flow cytometry using a PE Texas Red 
signal detector for PI staining and a FITC signal detector 
to detect Annexin V binding. 30,000 events were 
recorded by FACS using LSRII. Results are the average 
of three biological replicates analyzed and expressed as 




Statistical significance was determined using the 
Student’s t-test (unless stated otherwise); values of less 
than 0.05 were considered significant. Data are shown 
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